Ocelot Bio
Biotechnology ResearchView the employees at
Ocelot Bio-
Hong Qi Vice President, Tech Ops at OcelotBio, Inc
-
San Diego, California, United States
-
Top 5%
Karina Mena Senior Operations Manager at Ocelot Bio-
Escondido, California, United States
-
Rising Star
Jim Deng Senior Director, Corporate Strategy and New Product Planning at Ocelot Bio-
San Francisco Bay Area
-
Rising Star
Katherine Vega Stultz President and CEO | Board Member | Mentor | Company Builder| Talent Maximizer | Change Maker | CHIEF member-
San Francisco Bay Area
-
Top 5%
Louis Gonis Senior Director Manufacturing and Supply Chain at Ocelot Bio-
Bonners Ferry, Idaho, United States
-
Top 10%
Overview
Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a therapeutic peptide with a mechanism of action designed to selectively address portal hypertension induced complications of end-stage liver disease (ESLD). These complications include hepatorenal syndrome with acute kidney injury (HRS-AKI) and ascites, both of which may lead to serious and life-threatening outcomes. Ocelot Bio has initiated a Phase 2 clinical trial of OCE-205 in HRS-AKI, and the U.S. Food & Drug Administration (FDA) has granted OCE-205 Orphan Drug Designation in the treatment of hepatorenal syndrome. The company was founded by leading experts in therapeutic peptide development and is backed by a strong syndicate of investors including Venrock, RA Capital Management and Vivo Capital. For more information, visit www.ocelotbio.com.
-